<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/united-therapeutics-co-logo-1200x675.png/query-dj0yMDIyMTEwNzE1MjcxNw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/united-therapeutics-co-logo-1200x675.png/query-dj0yMDIyMTEwNzE1MjcxNw"/>United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 8,000 shares of the stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $398.55, for a total transaction of $3,188,400.00. Following the completion of the sale, the chief executive officer owned 130 shares in the company, valued at $51,811.50. This represents a 98.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this link.</p><h2>United Therapeutics Price Performance</h2><ul><li>The Top 3 Stock Picks at the World’s Greatest Hedge Fund</li></ul><p>UTHR stock opened at $396.50 on Thursday. The company's 50 day simple moving average is $314.12 and its 200-day simple moving average is $306.91. The firm has a market capitalization of $17.89 billion, a PE ratio of 15.48, a P/E/G ratio of 6.16 and a beta of 0.62. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $436.95. </p><p>United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same quarter last year, the business posted $5.85 EPS. The firm's revenue was up 11.7% compared to the same quarter last year.  As a group, sell-side analysts anticipate that  United Therapeutics Corporation will post 24.48 earnings per share for the current year. </p><h2>Hedge Funds Weigh In On United Therapeutics</h2><hr/><hr/><br/><ul><li>Liquidia: Court victory the awakening of an industry giant?</li></ul><p>Large investors have recently bought and sold shares of the stock. Chung Wu Investment Group LLC purchased a new position in shares of  United Therapeutics in the 2nd quarter valued at $29,000.  WealthCollab LLC raised its stake in shares of  United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 38 shares during the period.  Rakuten Securities Inc. raised its stake in shares of  United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 46 shares during the period.  SVB Wealth LLC purchased a new position in shares of  United Therapeutics in the 1st quarter valued at $32,000.  Finally, Geneos Wealth Management Inc. raised its stake in shares of  United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 85 shares during the period. Hedge funds and other institutional investors own  94.08% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of analysts recently issued reports on the stock. JPMorgan Chase &amp; Co. decreased their target price on shares of United Therapeutics from $350.00 to $330.00 and set an &#34;overweight&#34; rating on the stock in a research report on Tuesday, July 8th. Bank of America raised their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a &#34;neutral&#34; rating in a research report on Tuesday, September 2nd. UBS Group raised their target price on shares of United Therapeutics from $415.00 to $560.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, September 4th. Oppenheimer increased their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, September 5th. Finally, Jefferies Financial Group increased their price target on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, September 2nd. Nine investment analysts have rated the stock with a Buy rating and four have issued  a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $438.85.</p><ul><li>Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential</li></ul><p><b>Check Out Our Latest Analysis on United Therapeutics</b></p><h2>United Therapeutics Company Profile</h2><p> (Get Free Report)</p><p>United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than United Therapeutics</li><li>The 3 Best Blue-Chip Stocks to Buy Now</li><li>Oil Shorts Are Crowded, 3 Names That Could Bring on a Squeeze</li><li>What is the NASDAQ Stock Exchange?</li><li>Part of the Club: Robinhood &amp; AppLovin Soar on S&amp;P 500 Inclusion</li><li>Election Stocks: How Elections Affect the Stock Market</li><li>Despite Pullback, Rocket Lab Still Looks Primed for a Breakout</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VVRIUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VVRIUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at United Therapeutics?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for United Therapeutics and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://s3.amazonaws.com/assets.oxfordclub.com/emails/external_images/OXF_SEVEN_ALEX_STOCKS.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1920" height="1080" original-src="https://imageproxy.pbkrs.com/https://s3.amazonaws.com/assets.oxfordclub.com/emails/external_images/OXF_SEVEN_ALEX_STOCKS.jpg"/></p><div><p>He Called Nvidia at $1.10. Now, He Says THIS Stock Will…</p><p>The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million.  Now, the man who called Nvi...</p><p><span>The Oxford Club</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDc1OQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDc1OQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://files.admin.sovereignsociety.com/Background/ad%203%20image%20150px%20gsi%20bull%20market.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="150" height="200" original-src="https://imageproxy.pbkrs.com/https://files.admin.sovereignsociety.com/Background/ad%203%20image%20150px%20gsi%20bull%20market.jpg"/></p><div><p>Buffett, Gates and Bezos Dumping Stocks</p><p>The world's wealthiest individuals are making huge moves with their money.  Warren Buffett just liquidated b...</p><p><span>Banyan Hill Publishing</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDY2Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDY2Mg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250825083843_pushtrumpnew-1.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250825083843_pushtrumpnew-1.jpg"/></p><div><p>Why Trump’s “Smart Dollar” could rewrite the rules</p><p>MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar  Congress just approved President Trump's lates...</p><p><span>Stansberry Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDY0OQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDY0OQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://prioritygold.com/wp-content/uploads/2025/07/Genius-Act.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1560" height="442" original-src="https://imageproxy.pbkrs.com/https://prioritygold.com/wp-content/uploads/2025/07/Genius-Act.png"/></p><div><p>GENIUS Act: The Plot to Seize Your Cash?</p><p>A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...</p><p><span>Priority Gold</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDY3MA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDY3MA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250812113206_pushblur-1853262640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250812113206_pushblur-1853262640.jpg"/></p><div><p>Retire Comfortably with These New Monthly Income ETFs?</p><p>Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...</p><p><span>Investors Alley</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDYzMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDYzMA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://image.exct.investorplace.com/lib/fe8e13737460017471/m/1/8f1b63da-c494-483b-8703-2ecd5696e8de.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="499" height="339" original-src="https://imageproxy.pbkrs.com/https://image.exct.investorplace.com/lib/fe8e13737460017471/m/1/8f1b63da-c494-483b-8703-2ecd5696e8de.png"/></p><div><p>“Sell Nvidia before earnings”</p><p>Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...</p><p><span>InvestorPlace</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDYzNA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDYzNA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250825084343_pushcrypto-3569795640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250825084343_pushcrypto-3569795640.jpg"/></p><div><p>2013 Bitcoin miner reveals his trading system (free)</p><p>While everyone else is gambling on meme coins or chasing the next &#34;100x moonshot,&#34; our members are systematica...</p><p><span>Crypto Swap Profits</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDczMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDczMQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://marketingassets.marketwise.com/prod/images/brownstoneresearch/et/2025/06-Jun/BNF_AI_Metal_Spad+1%2C+4%2C+5+%2C+6.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="624" height="372" original-src="https://imageproxy.pbkrs.com/https://marketingassets.marketwise.com/prod/images/brownstoneresearch/et/2025/06-Jun/BNF_AI_Metal_Spad+1%2C+4%2C+5+%2C+6.png"/></p><div><p>$100 Trillion “AI Metal” Found in American Ghost Town</p><p>Jeff Brown recently traveled to a ghost town in the middle of an American desert…  To investigate what could...</p><p><span>Brownstone Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDcwNg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDcwNg"/></p></div></div></div>                     </div>                 </div></div>

UTHR

<p>United Therapeutics CEO Martine Rothblatt sold 8,000 shares at $398.55 each, totaling $3.19 million, reducing her ownership by 98.4% to 130 shares valued at $51,811.50. The transaction was disclosed to the SEC. The company's stock opened at $396.50, with a market cap of $17.89 billion and a P/E ratio of 15.48. Analysts have mixed ratings, with a consensus price target of $438.85, reflecting a "Moderate Buy" rating.</p>

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 8,000 Shares